Fig. 1. Illustration of a cooperative tumor-targeted drug delivery platform. DMXAA selectively disrupts the tumor vasculature and creates a unique artificial coagulation environment in a tumor. A15-PGA-CisPt are selectively recruited to the tumor by binding to fibrin clots via transglutamination.